The T-cell-specific adapter protein family: TSAd, ALX, and SH2D4A/SH2D4B by Lapinski, Philip E. et al.






The T-cell-specific adapter protein
family: TSAd, ALX, and
SH2D4A ⁄SH2D4B
Authors’ address
Philip E. Lapinski1, Jennifer A. Oliver1, Jennifer N. Bodie1, Francesc Marti1,
Philip D. King1
1Department of Microbiology and Immunology, University
of Michigan Medical School, Ann Arbor, MI, USA.
Correspondence to:
Philip D. King
Department of Microbiology and Immunology
University of Michigan Medical School
6606 Med Sci II
1150 West Medical Center Drive
Ann Arbor, MI 48109-5620, USA
Tel.: +1 734 615 9073
Fax: +1 734 764 3562
e-mail: kingp@umich.edu
Acknowledgements
Work relating to TSAd family adapter proteins in the King
Laboratory was supported by National Institutes of Health
grant RO1 AI050699, by the American Heart Association
grants 0615514Z and 0850170Z, and by funds from the




Printed in Singapore. All rights reserved
 2009 John Wiley & Sons A/S
Immunological Reviews
0105-2896
Summary: Adapter proteins play key roles in intracellular signal trans-
duction through complex formation with catalytically active signaling
molecules. In T lymphocytes, the role of several different types of adapter
proteins in T-cell antigen receptor signal transduction is well established.
An exception to this is the family of T-cell-specific adapter (TSAd) pro-
teins comprising of TSAd, adapter protein of unknown function (ALX),
SH2D4A, and SH2D4B. Only recently has the function of these adapters
in T-cell signal transduction been explored. Here, we discuss advances in
our understanding of the role of this family of adapter proteins in T cells.
Their function as regulators of signal transduction in other cell types is
also discussed.
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Introduction
Adapter proteins play central roles in intracellular signal trans-
duction pathways initiated by different cell surface receptors
in response to ligand recognition (1–3). Adapter proteins lack
catalytic activity but instead usually contain one or more mod-
ular-binding domains or recognition sequences for modular-
binding domains of other signaling proteins. As such, adapter
proteins participate in the formation of signaling complexes
with catalytically active molecules, resulting in direct or indi-
rect modulation of catalytic activity and ⁄or localization of cat-
alytically active molecules to substrates. Testimony to the
importance of adapter proteins in receptor signal transduction
is the finding that gene-targeted mice that lack expression of
specific adapter proteins frequently show signs of disease and
disturbances of tissue homeostasis often associated with early
mortality.
In T lymphocytes, the function of several different adapter
proteins such as growth receptor-bound-2 (Grb-2), Grb-2-
related adapter protein-2 (GRAP-2), Src homology-2 (SH2)-
domain-containing leukocyte protein of 76 kDa (SLP-76),
Fyn-binding protein (FYB), and linker of activated T cells
(LAT) has been extensively characterized (4–8). In contrast,
adapter proteins belonging to the T-cell-specific adapter
(TSAd) protein family have been less explored. This family
comprises of TSAd itself (also known as SH2D2A), adapter
protein of unknown function (ALX or HSH2D), SH2D4A, and
SH2D4B (9). In this article, we review current knowledge
relating to the function of these adapters in T cells. In addi-
tion, a role for these adapters in other cell types is discussed.
Identification and expression of TSAd family adapter
proteins
TSAd
TSAd was first identified in humans as part of a subtractive
cDNA library screen in which cDNA from peripheral blood
CD8+ T cells activated with CD3 plus CD28 monoclonal anti-
bodies (mAbs) was subtracted using cDNA prepared from the
Jurkat human T-cell leukemia cell line (10). From this screen,
an open reading frame (ORF) was identified that encoded a
389-amino acid protein that resembled a typical intracellular
adapter. Sequence inspection revealed a protein without any
recognizable catalytic activity but instead an SH2 domain
located in the center of the linear sequence with predicted
affinity for protein phosphotyrosine (Fig. 1). In addition, in
the region of the protein carboxyl to the SH2 domain, there
are five tyrosine residues, four of which are contained within
consensus motifs for phosphorylation by protein tyrosine kin-
ases (PTKs), plus several proline-rich regions. Potentially,
therefore, these sequences could serve as docking sites for
SH2 or protein tyrosine-binding domain (PTB)-containing or
SH3 domain-containing proteins, respectively (11).
Initial Northern blot analysis of different human tissues
revealed that TSAd expression was restricted to thymus,
spleen, and peripheral blood T lymphocytes (10). Further-
more, TSAd was not expressed in resting T cells but rather
was induced in both CD4+ and CD8+ T cells following their
activation with phorbol esters, phytohemagglutinin, or CD3
plus CD28 mAbs, consistent with the nature of the original
subtractive cDNA library screen (10). The kinetics of induced
expression were fairly rapid in that transcripts were detected
within hours and reached a plateau by 1 day after stimulation.
Western blot studies confirmed that the 52-kDa TSAd protein
was not expressed in resting T cells but was induced upon
T-cell activation with kinetics consistent with the increased
RNA expression (12). Such studies also revealed synergism
between CD3 and CD28 with regards to the induction of TSAd
protein. Expression of TSAd in human T cells appears to be
regulated in part by a cyclic adenosine monophosphate (AMP)
response element contained within the promoter of the TSAd
gene (13). However, activation of the cyclic AMP signal trans-
duction pathway alone is not sufficient for induction of TSAd
protein expression. Thus, a cyclic AMP analog, although able
to induce TSAd mRNA, is unable to induce TSAd protein
expression (14). Presumably, therefore, CD3 ⁄CD28 engage-
ment additionally results in the activation of pathways that
allow efficient translation of TSAd mRNA and ⁄ or promote
stability of TSAd protein.
Subsequent to the identification of TSAd in humans, TSAd
was identified in mice by two independent groups, both using
yeast-hybrid screening technology. Choi et al. (15) used a bait
protein comprising of the SH2 domain plus kinase domain of
the Src family PTK resting lymphocyte kinase (RLK). Rajagopal
et al. (16) used the Tec-family PTK RLK as a bait. TSAd was
found to interact with both types of bait protein and also
another Tec family PTK, interleukin-2-inducible T cell kinase
(ITK), hence the synonyms for TSAd, LCK-associated adapter
(LAD) and RLK ⁄ ITK-binding protein (RIBP), respectively.
Murine TSAd is a 366-amino acid protein that like human
TSAd contains a single SH2 domain (Fig. 1). Four out of the
five tyrosine residues found in the carboxyl region of human
TSAd are conserved in the carboxyl region of mouse TSAd as
is one of the proline-rich stretches. Interaction of TSAd with
LCK and RLK in yeast was shown to require a catalytically
active kinase domain in both cases. In addition, for the inter-
action with LCK, binding was shown to be abolished by a
point mutation of the LCK SH2 domain that prevented protein
phosphotyrosine recognition by this domain. These findings
suggested that the mechanism of interaction of TSAd with
PTKs involved PTK-mediated phosphorylation of TSAd
carboxyl region tyrosine residues followed by PTK SH2
domain recognition of the same tyrosine residues.
Similar to human TSAd, murine TSAd was initially reported
to be relatively restricted in expression to T cells and natural
killer (NK) cells. Northern blot analysis revealed strong
Fig. 1. TSAd (T-cell-specific adapter) family adapter proteins.
Positions of SH2 domains within linear sequences of each adapter are
indicated. Proline-rich stretches that are conserved between mouse and
human are shown in purple. Conserved tyrosine residues in consensus
phosphorylation motifs (NetPhos program) are also shown.
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expression in thymus, spleen, and peripheral blood mononu-
clear cells (15, 16). Transcripts were detected in T-helper 2
(Th2) and NK cell lines and in CD3 mAb-stimulated Th1 cells.
In the latter case, transcripts were induced as soon as 2 h after
stimulation (16). Induced expression of TSAd in murine
T cells is consistent, therefore, with findings in human T cells.
However, particularly in mouse T cells, TSAd protein does
appear to be expressed at functionally significant levels prior
to activation (15, 17). Furthermore, TSAd also appears to be
expressed at functionally significant levels in some other pri-
mary cell types in mice including lung epithelial cells, blood
vessel endothelial cells, and mature B cells (15, 18–20).
ALX
ALX was first identified as part of a search of databases for pro-
teins with SH2 domains with significant sequence similarity
to the SH2 domain of the c-ABL PTK (21). In humans, one
such novel 353-amino acid residue protein was identified that
contained a single SH2 domain at its amino-terminus (Fig. 1).
A homologous 364-amino acid residue protein was also iden-
tified in mice. The SH2 domains of human and murine ALX
show some similarity to the SH2 domain of c-Abl but in fact
are more homologous to the SH2 domains of TSAd, SH2D4A,
and SH2D4B (9). Aside from the SH2 domain, ALX shows lit-
tle sequence similarity with TSAd, SH2D4A, or SH2D4B.
However, like TSAd, outside of the SH2 domain, ALX contains
proline-rich stretches and tyrosine residues in consensus phos-
phorylation motifs. There are two proline-rich stretches and
two such tyrosine residues that are conserved between mouse
and human ALX.
ALX was initially named HSH2 for hematopoietic SH2 pro-
tein owing to its restricted expression in this lineage. Analyses
of mRNA expression revealed transcripts in peripheral blood
leukocytes, thymus, and spleen, but not a number of exam-
ined non-hematopoietic tissues (21). More detailed analysis at
both the mRNA and protein levels has shown that ALX is
expressed in both T and B cells (20, 22–24). However, in
contrast to TSAd, ALX expression is not increased in T cells
(or B cells) in response to activating stimuli.
SH2D4A ⁄ SH2D4B
Further searches of protein databanks reveal two other pro-
teins, SH2D4A and SH2D4B, which contain SH2 domains
with significant homology to the SH2 domains of TSAd and
ALX (Fig. 1). The SH2 domains of SH2D4A and SH2D4B are
located at the carboxyl ends of the proteins and show the
highest degree of homology to one another. In addition, there
is significant homology between SH2D4A and SH2D4B in
parts of the amino-terminal region (although there is no
homology of this region to regions outside of the SH2
domains of TSAd and ALX). The amino-terminal region of
SH2D4A contains a conserved tyrosine residue in a phosphor-
ylation consensus motif and a proline-rich stretch near the
SH2 domain. The amino-terminal region of SH2D4B contains
three conserved tyrosine residues in consensus phosphoryla-
tion motifs and a proline-rich stretch located in the same posi-
tion as that found in SH2D4A.
Analysis of expressed sequence tag and public microarray
databases indicate that SH2D4A is expressed at low levels in a
variety of human and murine tissues. With the use of a spe-
cific polyclonal antiserum, Lapinski et al. (25) demonstrated
that in quiescent human T cells, the 52-kDa SH2D4A protein
is expressed poorly but, like TSAd, is induced in response to
CD3 plus CD28 mAb activation. However, this inducibility is
not observed in murine T cells where the 48-kDa SH2D4A
protein is found prior to activation. Other hematopoietic cell
types in which SH2D4A has been found to be expressed
include B cells, macrophages, and dendritic cells. In these cell
types, SH2D4A is expressed constitutively and is not increased
in response to activating stimuli (25). One report has docu-
mented expression of SH2D4A in podocytes of kidney
glomeruli (26).
Less is known about the expression of SH2D4B. Database
analyses indicate a rare transcript in hematopoietic and non-
hematopoietic tissues. However, no information on protein
expression is yet available.
TSAd family adapter proteins and T-cell signal
transduction
TSAd
As a first approach to examine the function of TSAd in T cells,
several groups examined the influence of overexpression of
TSAd upon T-cell receptor (TCR)-induced activation of the
promoter for the intereukin-2 (IL-2) cytokine in T-cell lines
in vitro. However, conflicting results were obtained. Sunvold
et al. (12) reported that overexpression of TSAd in Jurkat cells
inhibited IL-2 promoter activity induced by the combination
of CD3 mAb and phorbol ester. In contrast, Marti et al. (27)
found that TSAd overexpression in Jurkat enhanced IL-2 pro-
moter activity in response to the same stimulus as well as in
response to CD3 plus CD28 mAb stimulation. Similarly, in
murine EL-4 T-lymphoma cells, Choi et al. (15) found that
overexpression of murine TSAd enhanced IL-2 promoter activ-
ity. It is possible that these discrepancies relate to the level of
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expression of TSAd in each instance, with a high level of
expression causing inhibition and more modest expression
resulting in augmentation of promoter activity. Whether such
differences are of physiological relevance is unclear. On the
one hand, augmented IL-2 promoter activity suggests a posi-
tive regulatory role for TSAd in T cells, and this role is consis-
tent with the finding that T cells from TSAd-deficient mice
synthesize reduced quantities of cytokines in response to TCR
stimulation (see the following paragraphs). On the other
hand, it is possible that TSAd may additionally perform a neg-
ative regulatory role during TCR signal transduction, perhaps
when expressed at higher levels at later time points after the
initiation of T-cell activation.
Following up on the identification of TSAd as an interaction
partner of LCK in yeast-hybrid systems, different groups have
examined physical and functional interactions between TSAd
and LCK in T cells. LCK is one of the first PTKs to become acti-
vated during the course of TCR signal transduction (1, 28).
Coengagement of the TCR and CD4 or CD8 coreceptors is
thought to result in local aggregation of LCK, leading to phos-
phorylation of a positive regulatory tyrosine residue (Y394)
contained in the LCK kinase domain with a resultant increase
in LCK kinase activity. This activated LCK then phosphorylates
tyrosine residues contained within immunoreceptor tyrosine-
based activation motifs (ITAMs) present in the cytoplasmic
tails of the TCR signaling chains, CD3 and TCR-f. The phos-
phorylated ITAMs are recognized by the SH2 domains of the
SYK family PTKf-associated protein of 70 kDa (ZAP70),
which is thus recruited to the TCR signaling complex where it
is juxtaposed to LCK and activated as a result of LCK-mediated
phosphorylation. Subsequently, ZAP70 phosphorylates tyro-
sine residues on the LAT transmembrane adapter protein that
then triggers signaling pathways that culminate in the activa-
tion of nuclear factor of activated T cells (NFAT), NFjB, and
activator protein-1 (AP-1) transcription factors. Together,
these transcription factors drive expression of numerous genes
involved in T-cell activation including cytokines such as IL-2.
With this backdrop, an ability of TSAd to engage and mod-
ulate LCK kinase activity directly or indirectly could provide a
basis for its ability to regulate TCR-induced cytokine synthesis.
Physical interaction between TSAd and LCK has been con-
firmed in T-cell lines and primary T cells both between trans-
fected and cell endogenous proteins (15, 17, 29–31). In
general, physical association is not apparent in resting T cells
but is induced rapidly in response to TCR engagement. Exten-
sive mutational analyses performed in vitro, in yeast, and in
T-cell lines have revealed at least two different mechanisms by
which TSAd interacts with LCK (15, 17, 29–31). First, as dis-
cussed previously, the LCK SH2 domain binds to phosphory-
lated tyrosine residues in the TSAd carboxyl region. In
transfected T-cell lines, as in yeast, LCK itself is able to phos-
phorylate these tyrosine residues and it is likely that cell
endogenous LCK performs this role during the course of T-cell
activation. Thus, the kinase activity of LCK promotes this form
of interaction. The second type of interaction involves LCK
SH3 domain recognition of the conserved proline-rich stretch
present in the TSAd carboxyl tail. As LCK does not interact
with TSAd in quiescent T cells, this form of interaction must
also be induced. Potentially, this could involve tyrosine phos-
phorylation-mediated exposure of the proline-rich stretch in
the TSAd carboxyl region and ⁄ or induced accessibility of the
LCK SH3 domain during the course of T-cell activation (see
subsequent paragraphs). Finally, the TSAd SH2 domain has
been shown to mediate a weak form of interaction with the
LCK kinase domain. In this case, the target tyrosine residue in
LCK appears to be the Y394-positive regulatory tyrosine resi-
due of the LCK kinase domain.
Some studies have reported an inhibitory effect of overex-
pressed TSAd upon TCR-mediated activation of LCK in Jurkat
(12, 29–31). This has been inferred from the ability of over-
expressed TSAd to: (i) block downstream signaling events that
are known to be dependent upon LCK activation such as
ZAP70 and LAT phosphorylation and activation of phospholi-
pase C-c (PLC-c); (ii) increase the phosphorylation of LCK
upon a carboxy-terminal negative regulatory tyrosine residue
(Y505) to a greater degree than it is able to increase the phos-
phorylation of the LCK Y394-positive regulatory tyrosine; and
(iii) block the tyrosine phosphorylation of a number of cellu-
lar proteins mediated by the expression of a Y505F constitu-
tively active LCK mutant. Furthermore, these inhibitory effects
have been shown to be mediated by the TSAd carboxyl region,
specifically, the same phosphorylated tyrosine residues and
proline-rich stretch that mediate interaction with the LCK SH2
and SH3 domains, respectively (29–31). An ability of over-
expressed TSAd to inhibit LCK activation would be consistent
with those studies that have reported an inhibitory effect of
TSAd overexpression upon IL-2 promoter activation. Again,
however, the physiological relevance of these overexpression
studies is questionable, as in T cells from TSAd-deficient mice,
activation of LCK in response to TCR triggering is impaired
not augmented (see subsequent paragraphs). Also, as LCK
kinase activity has not been directly examined in these overex-
pression studies, it is not entirely clear that the observed
effects are indeed a consequence of reduced LCK catalytic
activity per se or to some other influence. In this regard, it has
been proposed that TSAd may act as an LCK phosphorylation
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sink that redirects LCK kinase activity when overexpressed in
T cells (31).
Counter to the aforementioned findings, in vitro, recombi-
nant TSAd has been shown to activate directly the kinase activ-
ity of LCK, as measured by an ability of the kinase to
phosphorylate a peptide substrate and itself in in vitro kinase
assays (17). Although in those instances where overexpressed
TSAd has been shown to augment TCR-induced IL-2 promoter
activity, there has not been a parallel demonstration of
enhanced LCK activity; the finding that recombinant TSAd can
activate LCK in vitro is consistent with this augmentation as
well as the finding that TCR-induced activation of LCK is
impaired in TSAd-deficient T cells (17). The molecular mech-
anisms by which TSAd may activate LCK in T cells are dis-
cussed in more detail in the context of the TSAd-deficient
mouse (see the following section).
A nuclear function for TSAd
Aside from regulating proximal TCR signal transduction, TSAd
may also have a nuclear role in T cells. Indications of a nuclear
role were first suggested by the observation that a substantial
fraction of both transfected and endogenous TSAd is located
in the nucleus of Jurkat T cells (27). This nuclear translocation
is mediated by the TSAd SH2 domain, as a form of human
TSAd that contains a point mutation in the SH2 domain that
abrogates its ability to recognize phosphotyrosine ligands
(TSAd R120K) resides exclusively in the cytoplasm. In addi-
tion, the TSAd SH2 domain alone traffics to the nucleus when
transfected into Jurkat, whereas the same isolated SH2 domain
with an R120K point mutation does not. Recently, a form of
TSAd that lacks the central part of the carboxyl region that
contains a proline-rich stretch plus four tyrosine residues has
also been shown to be restricted in expression to the cell cyto-
plasm (30). This latter finding, therefore, illustrates the com-
plexity of the mechanisms controlling nuclear import of
TSAd, when one considers that the entire carboxyl region of
TSAd is apparently dispensable for nuclear import as evi-
denced by the nuclear translocation of the isolated TSAd SH2
domain (27). Nonetheless, available data are consistent with
the view that at least a component of the import process
involves TSAd SH2 domain recognition of a tyrosine-phos-
phorylated protein that transports TSAd into the nucleus.
To identify ligands of the TSAd SH2 domain that might be
involved in nuclear import, Marti et al. (27) performed pull-
down experiments of pervanadate-treated Jurkat lysates using a
glutathione s-transferase (GST)-TSAd SH2 domain fusion
protein. Two main tyrosine-phosphorylated proteins were
identified in these experiments of 95–100 and 57 kDa plus
minor species in the 35–40 kDa range. However, only the 95–
100-kDa protein was found in the T-cell nucleus as well as the
cytoplasm, suggestive of a role in nuclear transport. Using mic-
rochemical techniques, this ligand was unequivocally identi-
fied as p95 valosin-containing protein (VCP) (32). VCP is a
highly conserved large hexameric protein that belongs to the
adenosine triphosphatase (ATPase) associated with diverse cel-
lular activities (AAA) family (33, 34). It functions in numerous
different cellular processes that in part may be explained by its
role in the targeting of ubiquitylated proteins to the protea-
some for limited or complete proteolytic digestion (35–38).
VCP has previously been shown to be required for nuclear
import of the NFjB transcription factor in mammalian cells
(39). In addition, the yeast homolog of VCP, CDC48, has been
shown to be necessary for nuclear import of SPT23 and Mga2
transcription factors into the yeast nucleus (40, 41). In TCR-
stimulated T cells, VCP is phosphorylated upon a tyrosine resi-
due that is the penultimate tyrosine residue contained within
each hexameric subunit and in yeast phosphorylation of this
same residue in CDC48 has been shown to stimulate nuclear
mobilization of CDC48 (42–44). Interestingly, TSAd SH2
domain binding to VCP is dependent upon phosphorylation of
this same tyrosine residue, although biochemical analysis indi-
cates that TSAd does not bind directly to this residue (32). Most
importantly, in yeast cells, nuclear translocation of transfected
TSAd was shown to be dependent upon VCP ⁄ CDC48 as in yeast
that lack functional CDC48, nuclear translocation was not
observed (32). Together, these findings suggest a model in
which TCR engagement in T cells leads to phosphorylation of
VCP upon a penultimate tyrosine residue, which allows TSAd
SH2 domain recognition of this chaperone. In addition, the
same phosphorylation promotes nuclear import of VCP and, by
association, TSAd. However, whether VCP is essential for TSAd
nuclear mobilization in T cells has yet to be established.
The function of TSAd in the nucleus is largely unknown,
but it is of interest that when fused to the DNA-binding
domain (DBD) of the GAL4 transcription factor, TSAd is able
to drive transcription from a GAL4-operator luciferase repor-
ter in T-cell lines (27). Furthermore, this transcription trans-
activating ability depends upon an intact TSAd SH2 domain,
as a GAL4-DBD-TSAd (R120K) mutant is unable to activate
transcription from the same reporter despite that this fusion is
translocated to the nucleus owing to the presence of a strong
nuclear localization sequence in the GAL4-DBD component.
Therefore, in this system, TSAd appears to activate transcrip-
tion indirectly through interaction with a ligand of the SH2
domain that may or may not be VCP. It seems improbable that
Lapinski et al Æ TSAd family adapter proteins
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TSAd itself would directly bind to DNA. Rather, if TSAd were
naturally to function in gene transcription in the nucleus, then
this would likely involve physical interaction with a bona fide
DNA-binding protein. If so, TSAd might be considered as a
transcription adapter protein that facilitates complex forma-
tion between proteins with DNA-binding ability on the one
hand and proteins with transcription-activating ability on the
other.
TSAd-deficient mice
Rajagopal et al. (16) generated TSAd-deficient mice by homol-
ogous recombination in embryonic stem (ES) cells. Analysis
of young mice showed normal numbers of T cells and normal
ratios of different T-cell subsets in thymus, lymph node, and
spleen, leading to the view that TSAd is not required for T-cell
development or peripheral T-cell homeostasis. However,
functionally, splenic TSAd-deficient T cells were shown to
proliferate less and synthesize reduced amounts of IL-2 and
interferon-c (IFN-c) in response to CD3 and CD3 plus CD28
mAb stimulation in vitro. These last findings, therefore, clearly
illustrate the role of TSAd as a positive regulator of TCR signal
transduction.
Subsequent analysis of these mice confirmed and extended
these observations. Through crossing these mice to HY TCR
and AND TCR transgenic mouse strains, TSAd was shown to
be dispensable for the thymic development of major histo-
compatibility complex (MHC) class I- and class II-restricted
T cells, respectively (45). Both positive and negative selection
proceeded normally in the absence of TSAd. Gene chip micro-
array experiments of purified splenic CD4+ T cells from wild-
type and TSAd-deficient mice stimulated with CD3 and CD28
mAb confirmed a substantial reduction in the ability of TSAd-
deficient T cells to synthesize IL-2 and IFN-c (46). In addi-
tion, however, IL-4 mRNA was also found to be reduced in
stimulated TSAd-deficient T cells. At the protein level, HY TCR
transgenic and AND TCR transgenic TSAd-deficient peripheral
T cells were found to secrete reduced amounts of IL-2 and
IFN-c in response to stimulation with cognate peptide–MHC
complexes in vitro (authors’ unpublished data).
Role of TSAd as a regulator of LCK in primary T cells
Consistent with impaired cytokine synthesis, several different
TCR-induced cytoplasmic signaling events are dampened in
TSAd-deficient T cells (17). Thus, there is reduced activation
of the Ras small GTP-binding protein and downstream activa-
tion of mitogen-activated protein kinases (MAPKs) that con-
verge upon AP-1. In addition, calcium mobilization from
intracellular stores is reduced in TSAd-deficient T cells. These
defects can be traced backwards to reduced interaction of PLC-
c and the adapter protein Grb-2 with LAT, reduced tyrosine
phosphorylation of LAT, reduced activation of ZAP70 and
phosphorylation of the TCR-f chain and, ultimately, impaired
activation of LCK (17). This impaired activation of LCK is
apparent both as reduced phosphorylation of the Y394-posi-
tive regulatory tyrosine in the LCK kinase domain as well as
reduced kinase activity per se as measured in in vitro kinase
assays. In summary, therefore, these studies show that TSAd
has an essential role in the activation of LCK in peripheral
T cells and that this function, at least in part, accounts for the
role of TSAd as a regulator of T-cell function. Interestingly,
this role for TSAd appears to be restricted to peripheral T cells,
as in developing TSAd-deficient T cells, activation of LCK is
not impaired. Why activation of LCK in thymocytes does not
require TSAd is unknown at present.
It seems likely that the mechanism by which TSAd promotes
the activation of LCK in peripheral T cells involves interrup-
tion of intramolecular inhibitory interactions of the kinase. In
this regard, LCK SH2 domain recognition of phosphorylated
LCK Y505 is thought to promote an interaction of the LCK
SH3 domain with an LCK proline-rich stretch contained in a
linker region between the SH2 and kinase domains, the effect
of which is to close the kinase into an inactive conformation
(11, 28, 47, 48). Therefore, through binding to the LCK SH2
and SH3 domains, TSAd would drive LCK into an open con-
formation, from which point it has the potential to become
activated by phosphorylation upon Y394. Analysis of the
structural requirements of TSAd in terms of its ability to acti-
vate LCK kinase activity in vitro is consistent with this view.
Thus, mutation of the phosphorylated TSAd carboxyl region
tyrosine residues or of the central proline-rich stretch abro-
gates an ability of full-length TSAd to activate LCK in this assay
(17).
In response to TCR and CD4 ⁄CD8 coreceptor engagement,
it might be envisaged that activation of LCK initially proceeds
in a TSAd-independent manner. This process could occur as a
result of cross-phosphorylation on Y394 of those LCK mole-
cules that pre-exist in an open conformation. This activation
would result in an increase in the kinase activity of those LCK
molecules that would be sufficient to mediate phosphoryla-
tion of TSAd on carboxyl region tyrosine residues. Conse-
quently, TSAd would compete with LCK Y505 for binding to
the LCK SH2 domain and thereby drive additional LCK mole-
cules into an open primed conformation. In addition, at this
point, interaction of the proline-rich region of TSAd with
the LCK SH3 domain might promote or stabilize adoption of
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the open conformation in a manner that would not have been
possible prior to TSAd tyrosine phosphorylation either
because tyrosine phosphorylation is required to unmask the
proline-rich region and ⁄or that interaction of the proline-rich
region with the LCK SH3 domain cannot occur until displace-
ment of the LCK SH2 domain from phosphorylated Y505. Still
further stabilization of the open conformation might then
result from the action of the transmembrane protein tyrosine
phosphatase CD45, which dephosphorylates Y505 of LCK
(49). Once driven into the open conformation, full activation
of these LCK molecules would then occur as a result of cross-
phosphorylation on Y394.
In the aforegiven model, TSAd can be viewed as participat-
ing in a positive feedback loop that recruits additional LCK
molecules into cycles of activation, that is, LCK activation
results in TSAd phosphorylation, which leads to increased LCK
activation, which leads to increased TSAd phosphorylation,
and so on. However, recent unpublished data from our labo-
ratory suggest an alternative mechanism through which TSAd
may promote LCK activation in T cells. We have determined
that the SH2 domain of TSAd binds to a terminal phosphory-
lated tyrosine residue of the LAT molecule Y235. Indeed, LAT
is likely to represent one of the 35–40-kDa tyrosine-phos-
phorylated proteins identified in GST pull-down experiments
using the TSAd SH2 domain (27). Physical interaction of TSAd
with LAT has been demonstrated both in Jurkat and in pri-
mary mouse lymph node T cells. By virtue of a palmitoylation
modification, LAT is found almost exclusively in glycolipid-
enriched rich lipid rafts in T cells (50, 51). It is predicted
therefore that TSAd would be targeted to lipid rafts in T cells
during the course of TCR signaling. Indeed, in Jurkat cells,
TSAd translocates to lipid rafts in response to TCR triggering;
however, no such translocation of TSAd to lipid rafts is
observed in the JCam2.5 LAT-negative variant of Jurkat, thus
illustrating the critical role of LAT in TSAd targeting to rafts.
The question then is what is the purpose of TSAd translocation
to rafts? Might this translocation relate to the ability of TSAd
to regulate the activity of LCK? Preliminary information indi-
cates that this is in fact the case, in that TCR-induced physical
association of TSAd with LCK is seen to occur only within rafts
and is again dependent upon LAT. However, it is thought that
the LCK that resides within rafts has become recently activated
outside rafts, whereupon it translocates into rafts as a result of
activation-induced palmitoylation (52, 53). Furthermore,
within rafts, LCK is thought to set forward a series of events
that result in its phosphorylation by the C-terminal Src kinase
(CSK) upon Y505 that causes a refolding of LCK back into an
inactive conformation (2, 54–56). With this information,
TSAd might not contribute to the initial activation of LCK out-
side rafts but instead might function to prevent LCK inactiva-
tion within rafts by inhibiting this refolding.
T-cell migration
In addition to TCR signaling, TSAd has been reported to play a
positive regulatory role in chemokine receptor signaling in
T cells. Following upon their identification of TSAd as a bind-
ing partner of Gb subunits of heterotrimeric G proteins in
yeast hybrid screens, Park et al. (57) demonstrated that in
Jurkat, TSAd physically associates with Gb in response to stim-
ulation with the chemokines CXCL12 and CCL5. More impor-
tantly, short interfering RNA (siRNA)-mediated inhibition of
TSAd expression in Jurkat impeded directed migration
induced by CXCL12 and CCL5. Conversely, overexpression of
TSAd increased Jurkat cell CXCL12- and CCL5-induced migra-
tion. How, during the course of chemokine receptor signal-
ing, TSAd links Gb to the cellular migration response is
unclear. However, both CXCL12 and CCL5 were also shown
to promote physical interaction of TSAd with LCK and ZAP70
in Jurkat, both of which are known to be necessary for
chemokine-induced migration (58–60). Furthermore, inhibi-
tion of TSAd expression in Jurkat blocked chemokine-induced
activation of ZAP70, thus illustrating an important role for
TSAd in ZAP70 activation in this signaling pathway, analogous
to the same requirement for TSAd for ZAP70 activation during
TCR signal transduction (57). Based upon these findings, it
has been proposed that TSAd functions to recruit LCK and
ZAP70 to the Gb signaling complex, leading to the activation
of ZAP70 and the triggering of downstream responses such as
activation of MAPK and phosphorylation of focal adhesion
proteins which drive the chemotactic response.
TSAd and autoimmune disease susceptibility
Although young TSAd-deficient mice appear relatively normal,
with increasing age they present with features of lupus-
like autoimmune disease that include hypergammaglobulin-
emia and production of antibodies against self-antigens such
as single- and double-stranded DNA, cardiolipin, and self-
immunoglobulin (Ig) (46, 61). Frequently, there are signs of
glomerulonephritis associated with deposition of IgG com-
plexes in kidney glomeruli. In addition, leukocytic infiltration
into non-lymphoid organs is observed. In addition to devel-
oping spontaneous lupus-like disease in late age, young TSAd-
deficient mice show high susceptibility to experimental
pristane-induced lupus that manifests as the development of
much higher serum autoantibody titers and more severe
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glomerulonephritis compared with controls (46). In the spon-
taneous disease, disease development is associated with
increased numbers of peripheral T cells that show an activated
phenotype. This observation is consistent with the view that
the disease is of T-cell origin.
Exactly how T-cell immunological tolerance breaks down in
TSAd-deficient mice is uncertain. As noted before, T-cell-neg-
ative selection proceeds normally in the absence of TSAd. In
addition, natural CD4+CD25+ T-regulatory cells (Tregs) that
normally guard against the development of autoimmune dis-
ease are found in normal numbers in the thymus and periph-
eral lymphoid organs of TSAd-deficient mice, and no
decreases in natural Treg number are apparent with age
(authors’ unpublished data). We have also determined that
adaptive Tregs are generated normally in TSAd-deficient mice
in response to transforming growth factor-b (TGFb) stimula-
tion. Moreover, TSAd-deficient Tregs show an increased and
not decreased capacity to suppress T-cell proliferative
responses in vitro. Thus far, the only abnormality that has been
observed in TSAd-deficient mice that might account for auto-
immune disease development is a reduced susceptibility of
T cells to apoptotic death in vivo (45, 46, 61). An impaired
T-cell death response in TSAd-deficient mice was revealed
following immunization of mice with staphylococcal super-
antigen. After an initial normal T-cell clonal expansion,
responding cells failed to undergo apoptotic death to the same
extent as that seen in controls. In other mouse models where
there is an impaired death response of peripheral T cells, this
is usually associated with the development of lupus-like dis-
ease (61, 62). However, the molecular basis for the impaired
T-cell death response in TSAd-deficient mice is uncertain.
Gene chip analyses and follow-up protein expression analyses
of activated TSAd-deficient and wildtype T cells do not reveal
any obvious increases in the expression of anti-apoptotic
genes or decreased expression of pro-apoptotic genes in
TSAd-deficient T cells that might account for the resistance to
death. One exception is IL-2, which is known to promote
T-cell death in vivo, including superantigen-induced death
(63–65). TSAd-deficient T cells synthesize severalfold less IL-2
protein than control T cells following superantigen stimula-
tion in vivo (46). Therefore, impaired synthesis of IL-2 may be
a significant factor that promotes the development of lupus-
like disease in TSAd-deficient mice. However, a caveat to this
interpretation is the normal frequency and function of Treg in
TSAd-deficient mice. IL-2 is required for maintenance of Treg
number and Treg function in mice (66–71). Thus, unless one
envisages that IL-2 levels in TSAd-deficient mice are dimin-
ished to an extent that they impact upon T-cell death but not
Treg number and function, then some other factor must be
responsible for impaired T-cell death and the development of
autoimmune disease in this model. One other group did not
observe an impaired T-cell death response in TSAd-deficient
mice following administration of superantigen (20).
Whether mutations or polymorphisms of the TSAd gene
contribute or do not contribute to the development of sys-
temic lupus erythematosus has not been examined in humans.
However, TSAd polymorphisms do appear to be significantly
associated with the autoimmune disease multiple sclerosis in
humans (72, 73). The human TSAd promoter contains differ-
ing numbers of GA repeats (13–33), and, interestingly, TSAd
alleles with fewer numbers of repeats (GA13 or GA16) show
significant association with multiple sclerosis in Scandinavian
cohorts. Consistent with findings in mice that loss of expres-
sion of TSAd predisposes toward autoimmune disease, indi-
viduals that are homozygous for TSAd alleles with fewer
numbers of GA repeats express reduced amounts of TSAd
(72). A similar association of GA13 or GA16 TSAd alleles with
disease has also been observed in juvenile rheumatoid arthritis
and, recently, chronic inflammatory demyelinating polyradi-
culoneuropathy (74, 75). However, in the case of the demye-
linating disorders (multiple sclerosis included), it is not
certain if TSAd allele associations with disease reflect a role for
altered TSAd expression in disease etiology or, alternatively,
can be explained by a very close linkage of the TSAd gene to
the gene for neurotrophic tyrosine kinase receptor 1.
ALX
As with TSAd, a function for ALX in T-cell signal transduction
was first suggested by studies that examined the effect of its
overexpression in Jurkat T cells. Overexpression was found to
inhibit IL-2 promoter activity induced by TCR plus CD28 mAb
stimulation or stimulation with staphylococcal superantigen
(22). Dissection of this effect upon IL-2 promoter activation
revealed that the greatest inhibition could be observed with a
promoter that is comprised of the CD28 response element plus
an AP-1 binding site (RE ⁄AP1), whereas minimal inhibition
was observed using a promoter containing AP-1-binding sites
alone. Thus, the overexpressed ALX appears to target signaling
pathways that activate the CD28 RE. Further studies examined
the structural requirements of ALX with regards its ability to
inhibit RE ⁄AP promoter activity in Jurkat (76). Mutation of
different tyrosine residues or of proline-rich regions in the
ALX sequence, alone or in combination, did not affect inhibi-
tory activity. In contrast, point mutation of the ALX SH2
domain to prevent recognition of phosphotyrosine ligands
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abrogated inhibitory activity. Together with the finding that
the ALX SH2 alone was sufficient to inhibit promoter activa-
tion, these studies pointed to a critical role for the SH2 domain
of ALX in this experimental system.
During the course of these studies, it was noticed that like
TSAd, a fraction of ALX resides in the nucleus of Jurkat cells
(77). In addition, TCR plus CD28 mAb stimulation of Jurkat
was shown to result in export of ALX out of the nucleus to the
cytoplasm. This observation led to the identification of a con-
served LxxxLxxL nuclear export sequence (NES) in the ALX
carboxyl region. Mutation of this sequence prevented TCR-
⁄CD28-mediated nuclear export of ALX. Similarly, inhibition
of the CRM-1 protein, commonly implicated in nuclear export
of proteins, using leptomycin B, blocked nuclear export
showing the critical role of the CRM-1-mediated pathway as
well as the LxxxLxxL sequence of ALX in this process. The
mechanism by which ALX enters the nucleus is less well
understood although in transfected epithelial cell lines, dele-
tion of the entire carboxyl region of ALX prevents nuclear
import. Also unclear is the purpose of ALX nuclear transloca-
tion. However, nuclear export appears to be important for the
full inhibitory effect of ALX upon TCR ⁄CD28 or superantigen-
induced RE ⁄AP activation in Jurkat. Thus, mutation of the NES
in ALX abrogates the inhibitory effect (77).
ALX-deficient mice
To examine the physiological role of ALX in T cells, ALX-defi-
cient mice were generated by homologous recombination in
ES cells (78). In these mice, T-cell development was found to
proceed normally, and numbers and ratios of different T-cell
subsets in peripheral lymphoid organs were unaffected by
ALX loss. However, purified peripheral T cells from ALX-defi-
cient mice synthesized increased amounts of IL-2 in response
to CD3 plus CD28 mAb stimulation in vitro and in response to
antigenic stimulation in vitro following priming to the same
antigen in vivo. These findings, therefore, are consistent with
the result that overexpressed ALX inhibits TCR- ⁄CD28-
induced activation of the IL-2 promoter in Jurkat.
Investigations into the molecular basis for the T-cell hyper-
responsive phenotype in ALX-deficient mice yielded some
surprising findings in that most canonical TCR signaling path-
ways seemed to be unaffected including intracellular calcium
mobilization and pathways leading to the activation of AP-1
(78). However, one pathway that seemed to be constitutively
activated in ALX-deficient T cells was the p38 MAPK signaling
pathway. A similar phenotype of increased TCR-induced IL-2
synthesis associated with augmented activation of p38 has
been described in knockout mice that lack expression of the
LAX transmembrane adapter that is related to LAT (79, 80).
This finding suggests that ALX and LAX function in the same
negative signaling pathway to regulate IL-2 synthesis in
T cells. Along these lines, ALX and LAX have been shown to
physically associate with one another when both are transfect-
ed into Jurkat and the HEK293 embryonic kidney cell line
(78, 81). Mutational analysis has revealed that this association
is constitutive and does not require LAX tyrosine residues or
the ALX SH2 domain. Cotransfection of ALX and LAX into
Jurkat results in LAX tyrosine phosphorylation and this phos-
phorylation appears to depend upon LCK as LAX is not phos-
phorylated on tyrosine residues when both proteins are
transfected into an LCK-negative variant of Jurkat. Further-
more, the ALX SH2 domain was found to pull-down LCK
from Jurkat lysates. These findings have led to a model in
which ALX is conceived to bind and juxtapose LCK to LAX
leading to LAX phosphorylation with resultant suppression of
the p38 pathway (81). This model is interesting but is based
thus far only upon studies involving overexpressed proteins in
cell lines or upon in vitro protein association experiments.
Apart from the demonstration of association between cell
endogenous proteins, strong support for this model would
come from the finding that in ALX-deficient T cells, LAX is
not phosphorylated upon tyrosine residues during the course
of TCR signal transduction. This finding would illustrate an
essential role for ALX in the phosphorylation of this trans-
membrane adapter. Additionally, although overexpression of
LAX in Jurkat causes inhibition of TCR- ⁄CD3-induced RE ⁄ AP
promoter activity, this inhibition is found not to depend upon
LAX tyrosine phosphorylation (81).
Although ALX and TSAd have opposing effects in T cells,
Perchonock et al. (20) generated ALX ⁄ TSAd double deficient
mice to study the influence of combined loss of both proteins
upon T-cell development and function. Similar to single defi-
cient mice, young double deficient mice showed normal
T-cell development and normal numbers and ratios of periph-
eral T-cell subsets. With regards to IL-2 synthesis, double defi-
cient peripheral T cells behaved similar to ALX single deficient
T cells in that they synthesized increased amounts of IL-2 in
response to CD3 plus CD28 mAb stimulation. Also, double
deficient T cells again showed constitutive activation of p38.
Therefore, the effect of loss of ALX expression associated with
constitutive p38 activation appears to override the effect of
loss of TSAd expression even though in single TSAd-deficient
mice this results in impaired TCR-mediated activation of LCK
(17). Whether TCR-mediated activation of LCK is normal in
double deficient mice has not been determined.
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Unlike TSAd-deficient mice, there is scant evidence that
ALX-deficient mice develop spontaneous autoimmune disease,
although with increasing age some mice show splenomegaly
and increased numbers of T cells with an activated phenotype
(78). This observation is in accordance with the finding that
superantigen-mediated deletion of peripheral T cells is unaf-
fected in ALX-deficient mice. However, the same group that
reported these findings was also unable to demonstrate
impaired superantigen-induced T-cell death in TSAd-deficient
mice or in ALX ⁄TSAd double deficient mice. Whether ALX-
deficient mice show or do not show increased susceptibility to
experimentally induced lupus has not been determined.
SH2D4A ⁄ SH2D4B
To identify ligands of SH2D4A, we performed GST pull-down
experiments from Jurkat lysates using the full-length SH2D4A
protein (authors’ unpublished data). In these experiments, a
major protein band of 80 kDa was identified that upon micro-
chemical analysis was determined to represent a mixture of
two SH3 domain-containing adapter proteins, hematopoietic-
specific protein-1 (HS1), and cortactin, with the former rep-
resenting the major component (82, 83). For HS1, interaction
with SH2D4A was further demonstrated by coimmunoprecip-
itation and Western blotting in both Jurkat and primary
human T cells. Interaction was constitutive and not modulated
in response to TCR engagement. Two other specific ligands of
SH2D4A, SH3P7 and SH3P8, were identified in yeast-hybrid
screens. Like HS1 and cortactin, these proteins contain SH3
domains (84, 85). Interaction of SH2D4A with these different
SH3 domain-containing proteins suggested a potential func-
tion for SH2D4A in T-cell signal transduction, possibly
through regulation of the actin cytoskeleton. HS1, for exam-
ple, has been shown to control the accumulation of F-actin in
the immunological synapse in T cells (86). Furthermore,
T cells from HS1- and SH3P7-deficient mice show reduced
proliferation and cytokine secretion in response to TCR stimu-
lation in vitro (87, 88). In support of a role for SH2D4A in TCR
signal transduction, overexpression in Jurkat was found to
block TCR-induced expression of the CD69 early activation
marker.
To address definitively if SH2D4A played an essential role in
TCR signal transduction, we generated SH2D4A-deficient
mice (25). In these mice, T-cell development and peripheral
T-cell homeostasis was normal. Furthermore, peripheral
T cells in SH2D4A-deficient mice synthesized normal levels of
cytokines, proliferated normally, and showed normal death
responses upon stimulation with CD3 and CD28 mAb. Addi-
tional evidence that SH2D4A is not required for T-cell func-
tion came from the finding that SH2D4A-deficient mice were
able to clear Listeria monocytogenes infection in vivo with similar
efficiency as wildtype littermate control mice. To address if
there was a species difference between mouse and humans
with respect to a role for SH2D4A in T cells, we examined the
effect of knockdown of SH2D4A expression in primary human
T cells using siRNAs (25). However, despite the effectiveness
of siRNA in reducing SH2D4A expression, no effect of this
reduced expression upon CD3 plus CD28 mAb-induced T-cell
cytokine synthesis, proliferation, or survival was apparent.
SH2D4A, therefore, appears to be dispensable for T-cell signal
transduction. Given the high degree of homology between
SH2D4A and SH2D4B, it is possible that SH2D4B substitutes
for the function of SH2D4A in SH2D4A-deficient T cells.
SH2D4B-deficient mice have not yet been reported, and
whether SH2D4B has or does not have a non-redundant role
in T cells is unknown. Should a role for SH2D4B in T-cell sig-
nal transduction not be revealed in SH2D4B-deficient mice,
this would emphasize the importance of generating
SH2D4A ⁄ SH2D4B double deficient mice to address any poten-
tial issue of redundancy.
Other functions of TSAd family adapter proteins
TSAd
TSAd has been identified as an interacting partner of several
other types of bait protein in yeast-hybrid screens. These
include PLC-c, phosphatidylinositol-3-kinase, the Grb-2 adap-
ter, Smad proteins, the MEKK2 MAPK kinase (MAP3K), and
the vascular endothelial growth factor receptor-2 (VEGFR2)
(18, 89–93). In those instances where convincing interaction
between cell endogenous proteins in mammalian cells has not
been subsequently demonstrated, given that yeast-hybrid
screening frequently yields false-positive results, these find-
ings should be taken with caution. This approach is particu-
larly true for interactions involving TSAd in yeast because of
the strong intrinsic transcription trans-activating potential of
the full-length TSAd protein (27). Clearly, however, for some
of these binding partners, such as MEKK2 and VEGFR2, the
interaction is meaningful and has been shown to be of physio-
logical relevance.
Big MAPK activation
MEKK2 is a MAP3K in the big MAPK signaling pathway (91).
It associates with and activates the MAP2K MEK5, which in
turn activates the big MAPK ERK5. In cell lines such as
HEK293, activation of MEKK2 is required for the activation of
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ERK5 during the course of epidermal growth factor receptor
(EGFR) signaling or stimulation of cells with sorbitol, H2O2,
or expression of a constitutively active form of the c-Src PTK.
In response to these stimuli, MEKK2 is phosphorylated on
tyrosine residues, and this phosphorylation has been shown to
be necessary for an increase in MEKK2 kinase activity and
stimulation of the big MAPK response. TSAd was identified as
an interacting partner of the amino-terminal regulatory
domain of MEKK2 in yeast (91, 92). The region of MEKK2
required for interaction was shown to be contained within
residues 228–282 of the amino-terminal domain, although
the region of TSAd protein that is involved in binding was not
clearly identified. Nonetheless, antisense knockdown of TSAd
or inhibition of the association between MEKK2 and TSAd,
through expression of the MEKK2 228–282 polypeptide in
cells, inhibited MEKK2 tyrosine phosphorylation and the acti-
vation of ERK5 (92). These findings show that TSAd interac-
tion with MEKK2 is required for MEKK2 tyrosine
phosphorylation and activation of ERK5 stimulated by the
aforementioned agents. For all of the stimuli, MEKK2 tyrosine
phosphorylation was shown to be mediated by Src family
PTKs (92). One way to explain these findings is that TSAd
functions as an adapter protein in these responses that juxta-
poses Src family PTKs to MEKK2, permitting effective MEKK2
phosphorylation. Indeed, TSAd becomes phosphorylated in
HEK293 cells in response to these agents, which would allow
association with the LCK SH2 domain (92). Furthermore,
based upon findings in T cells, there is a strong likelihood that
TSAd would promote the activation of Src family PTKs, which
would constitute an additional basis for the requirement of
TSAd in MEKK2 phosphorylation. In T cells themselves, the
significance of TSAd interaction with MEKK2 has not been
explored. However, it is of note that upon stimulation of the
murine D10 T-cell line with antigen-presenting cells (APCs)
bearing specific antigenic peptide–MHC complexes, TSAd is
seen to redistribute with MEKK2 to the region of close T cell–
APC apposition (91).
Angiogenesis
VEGFR2 is a receptor PTK that upon recognition of its ligand,
VEGF-A, promotes blood vessel endothelial cell growth, sur-
vival, and migration (94). VEGFR2 is essential for blood vessel
vasculogenesis and angiogenesis (the growth of new blood
vessels from existing blood vessels). During the course of
VEGFR2 signal transduction, several cytoplasmic region tyro-
sine residues become phosphorylated, including residue Y951
located in the kinase insert domain. In yeast-hybrid screens,
TSAd was identified to interact directly with this tyrosine resi-
due (89). In addition, in human umbilical vein endothelial
cells and porcine aortic endothelial cells, VEGF-A stimulation
was shown to induce association between cell endogenous
VEGFR2 and TSAd as well as TSAd tyrosine phosphorylation
and interaction of TSAd with c-Src (18, 89). Importantly,
TSAd association with phosphorylated Y951 of VEGFR2 was
shown to be required for VEGFR2-induced actin stress fiber
formation and migration of endothelial cells in vitro. Thus, an
Y951F mutation of the VEGFR2 cytoplasmic domain, a phos-
phorylated VEGFR2 peptide spanning Y951, and TSAd knock-
down all resulted in inhibition of these VEGFR2-induced
responses (18). Moreover, in TSAd-deficient mice, growth of
injected fibrosarcoma cells was found to be significantly
impaired compared with growth of the same tumor in control
mice and this correlated with a reduced blood vessel angio-
genesis response toward the tumor in the TSAd-deficient mice
(18). These findings demonstrate an important role for TSAd
in blood vessel angiogenesis through association with VEG-
FR2. The precise role played by TSAd in this pathway remains
uncertain. However, activation of c-Src is likely a key event in
VEGFR2-induced endothelial migration (95). Therefore, an
ability of TSAd to promote the activation of Src-family PTK, as
demonstrated in T cells, may again provide a basis for its
involvement.
PDGFR signaling
One other signaling pathway in which TSAd has been impli-
cated is that initiated by another receptor PTK, the platelet-
derived growth factor receptor (PDGFR). Based upon the
identification of TSAd transcripts and protein in lung tissue,
Park et al. (19) asked if TSAd was involved in the PDGFR sig-
naling pathway in lung epithelial cell lines. Stimulation of
these cell lines with PDGF resulted in TSAd tyrosine phosphor-
ylation and physical association with the PDGFR and Grb-2.
Interaction of TSAd with the PDGFR was shown to be medi-
ated by TSAd SH2 domain recognition of a tyrosine residue
contained in the kinase insert domain of the PDGFR, whereas
Grb-2 association with TSAd was shown to involve Grb-2 SH2
domain recognition of TSAd carboxyl region tyrosine residue
Y292. The significance of these interactions for PDGFR signal-
ing is unclear. However, that they may potentiate PDGFR sig-
naling is suggested by the observations that overexpression of
wildtype TSAd but not an Y292F TSAd mutant in a lung epi-
thelial cell line augments PDGFR-mediated activation of AP-1.
Conversely, expression of the TSAd SH2 domain alone in these
cells inhibits PDGF-mediated AP-1 activation (19).
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ALX
One other function that has been attributed to ALX is regula-
tion of B-cell apoptosis. Principally, this contention has been
based upon the finding that overexpression of ALX in the
WEHI-231 B-lymphoma cell line inhibits antigen receptor-
induced death associated with increased activation of the JNK
MAPK and inhibition of mitochondrial depolarization (23).
Furthermore, stimuli that promote B-cell death such as anti-
gen receptor engagement and IL-21 treatment significantly
reduce the expression of ALX, whereas stimuli that promote
B-cell survival such as CD40, BAFF receptor, TLR4, and TLR9
engagement cause an upregulation of ALX expression (23,
24). These findings have led to the contention that ALX func-
tions as an anti-apoptotic protein in B cells. Despite these find-
ings, however, in ALX-deficient mice, B cells develop
normally, show normal proliferative and survival responses to
a panel of different stimuli in vitro, and function normally in
the generation of a T-cell-dependent antibody response to
nominal antigen in vivo (78). In addition, the lack of a B-cell
phenotype in these mice cannot be explained by an overlap-
ping function with TSAd, as B cells in ALX ⁄TSAd double defi-
cient mice also function normally (20). Therefore, unless
SH2D4A or SH2D4B is able to substitute for the function of
ALX and TSAd in B cells, these findings force the conclusion
that B-cell apoptosis is in fact not regulated by ALX.
Conclusions
In the last several years, considerable advances have been
made with respect to our understanding of the function of
TSAd and ALX in T cells and other cell types, aided principally
by the development and characterization of knockout mouse
models of these adapter proteins. TSAd has been found to
function as an important positive regulator of TCR-induced
T-cell cytokine synthesis, chemokine-induced T-cell migra-
tion, VEGFR2-induced endothelial cell migration, and blood
vessel angiogenesis, and EGFR-induced activation of the big
MAPK pathway. In contrast, it has become apparent that ALX
functions as a negative regulator of TCR-induced cytokine
synthesis in T cells. One unifying theme that has emerged
from these studies that may explain these different roles is an
ability of these adapter proteins to regulate the activation
and ⁄or localization of Src family PTK to substrates at the outset
of signaling cascades. Thus, in T cells, TSAd acts to activate
LCK and ⁄ or potentiate its activation in lipid rafts, whereas
ALX may act to juxtapose LCK to LAX and thereby participate
in a negative feedback pathway that controls the TCR signaling
response. TSAd in T cells may play a similar LCK-activating
role during the course of chemokine-induced migration. In
the VEGFR2-induced endothelial cell migration response,
TSAd is likely to be an important factor controlling the activa-
tion of Src and in EGFR-induced activation of the big MAPK
pathway, TSAd may serve to both activate Src and localize this
PTK to MEKK2.
A number of questions regarding the role of this family of
adapters have yet to be answered. First and foremost, the
function of SH2D4A has remained elusive, and the role of
SH2D4B has yet to be studied. Potentially, the lack of pheno-
type of the SH2D4A-deficient mouse can be explained by an
overlapping function with SH2D4B and ⁄ or TSAd or ALX, and
this possibility needs to be addressed. Also unclear is the pur-
pose of nuclear translocation of TSAd and ALX and whether
this relates to a transcription function of these adapter proteins
in T cells. Finally, the precise mechanisms by which loss of
TSAd expression predisposes toward the development of auto-
immune disease in mice has not yet been firmly established
and warrants further investigation. Given the reported associa-
tion of TSAd promoter polymorphisms with multiple sclero-
sis, demyelinating polyradiculoneuropathy, and juvenile
rheumatoid arthritis, delineating these mechanisms are of
potential direct relevance to our understanding of the etiology
of these human autoimmune diseases.
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